CalciMedica Inc. (NASDAQ:CALC) Short Interest Down 47.6% in July

CalciMedica Inc. (NASDAQ:CALC) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 47,400 shares, adecreaseof47.6% from the July 15th total of 90,500 shares. Based on an average trading volume of 63,400 shares, the short-interest ratio is currently 0.7 days. Approximately0.8% of the shares of the stock are sold short. Approximately0.8% of the shares of the stock are sold short. Based on an average trading volume of 63,400 shares, the short-interest ratio is currently 0.7 days.

Hedge Funds Weigh In On CalciMedica

Large investors have recently modified their holdings of the company. First Manhattan CO. LLC. purchased a new stake in shares of CalciMedica during the 1st quarter valued at about $25,000. 180 Wealth Advisors LLC purchased a new stake in shares of CalciMedica during the 1st quarter valued at about $31,000. Sound View Wealth Advisors Group LLC purchased a new stake in shares of CalciMedica during the 2nd quarter valued at about $32,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of CalciMedica during the 1st quarter valued at about $45,000. Finally, Cetera Investment Advisers raised its holdings in shares of CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after buying an additional 9,045 shares during the period.

CalciMedica Stock Performance

NASDAQ CALC opened at $2.78 on Wednesday. The business’s 50-day moving average price is $2.40 and its 200 day moving average price is $2.12. The company has a market capitalization of $38.84 million, a PE ratio of -1.74 and a beta of 1.33. The company has a current ratio of 5.45, a quick ratio of 5.45 and a debt-to-equity ratio of 1.39. CalciMedica has a twelve month low of $1.42 and a twelve month high of $5.97.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, hitting analysts’ consensus estimates of ($0.40). On average, research analysts predict that CalciMedica will post -2.21 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a report on Thursday, May 15th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $16.00.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.